Meta-Analysis of Acetylsalicylic Acid Desensitization in Patients With Acute Coronary Syndrome
2019
Acetylsalicylic acid (ASA) hypersensitivity represents a clinical challenge in
acute coronary syndrome(ACS) patients urgently requiring ASA for antiplatelet therapy. ASA
desensitizationhas been reported with successful outcomes in cardiac patients. The aim of this review is to determine the safety and efficacy of ASA
desensitization therapyin ACS patients. A PubMed database search was conducted for articles containing combinations of keywords, “aspirin
desensitization” or “aspirin hypersensitivity” and “
acute coronary syndrome” between January 1, 1990 and August 1, 2018. The primary end point was
desensitizationprotocol success. Secondary end points included hypersensitivity adverse events and ASA discontinuation due to hypersensitivity adverse events at follow-up. Fifteen reports consisting of 480 ACS patients with previous hypersensitivity to ASA were included. The pooled
desensitizationsuccess rate was 98.3% (95% confidence interval: 97.2% to 99.5%). There was no statistical difference in outcomes between protocols ≤ 2 hours and > 2 hours in duration (96.3[92.3 to 100.3]% vs 97.2[94.6 to 99.8]%; p = 0.71). Protocols with > 6 dose escalations were associated with higher success rates compared to those with ≤ 6 doses (99.2[97.9 to 100.4]% vs 95.4[93 to 97.8]%; p = 0.007). At follow-up between 1 and 46 months (mode 12 months), zero hypersensitivity adverse events were reported. Consequently, no ASA discontinuations were related to hypersensitivity adverse events. In conclusion, ASA
desensitization therapyis safe and effective in patients with ACS. Protocols with > 6 dose escalations may be optimal for ASA
desensitizationin ACS patients.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
35
References
4
Citations
NaN
KQI